730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumorsDaneng Li, Giovanni Selvaggi, Hirva Mamdani et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0